GAS2L2 as A Drug Target Or Biomarker for Diseases (G246176)
GAS2L2 as A Drug Target Or Biomarker for Diseases
GAS2L2 (Glycophosphorylase 2-like 2) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the glycophosphorylase (GPC) family, which is involved in the breakdown of glycophospholipids. GPCs are known to be involved in the regulation of cellular signaling pathways, including those related to cell adhesion, migration, and survival.
Recent studies have identified GAS2L2 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to GAS2L2's involvement in the regulation of cellular processes that are often disrupted in these conditions, as well as its potential to modulate cellular signaling pathways that are involved in disease progression.
One of the key reasons for the potential of GAS2L2 as a drug target is its role in the regulation of cell adhesion. GAS2L2 is a critical enzyme in the GPC family, and its activity is required for the formation of adhesion molecules on the cell surface. These molecules, known as cadherins, help to maintain the integrity of tissues and are involved in various physiological processes, including cell signaling, migration, and survival.
Studies have shown that GAS2L2 is often expressed in tissues that are highly dependent on cell adhesion, such as cancer cells, neuroblastoma cells, and melanoma cells. In addition, GAS2L2 has been shown to play a role in the regulation of cell-cell adhesion, which is critical for the development and maintenance of tissues and organs.
Another potential drug target for GAS2L2 is its role in the regulation of cellular signaling pathways that are involved in disease progression. GAS2L2 is involved in the regulation of several signaling pathways that are involved in cancer growth and progression, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway.
Studies have shown that GAS2L2 is often expressed in tissues that are highly dependent on these signaling pathways, such as cancer cells, neurodegenerative diseases, and autoimmune disorders. In addition, GAS2L2 has been shown to play a role in the regulation of cellular signaling pathways that are involved in disease progression, including the regulation of angiogenesis, cancer cell metastasis, and neurodegeneration.
In addition to its potential as a drug target, GAS2L2 has also been identified as a potential biomarker for several diseases. Its involvement in the regulation of cell adhesion and cellular signaling pathways makes it an attractive candidate for the development of diagnostic tests for these conditions.
GAS2L2 has been shown to be involved in the regulation of several cellular processes that are involved in disease progression, including the regulation of angiogenesis, cancer cell metastasis, and neurodegeneration. Its activity is also involved in the regulation of cell-cell adhesion, which is critical for the development and maintenance of tissues and organs.
GAS2L2 is a key enzyme in the GPC family and its activity is required for the formation of adhesion molecules on the cell surface. Its involvement in the regulation of cellular signaling pathways that are involved in disease progression makes it an attractive candidate for the development of diagnostic tests for these conditions. Further research is needed to fully understand the role of GAS2L2 as a drug target or biomarker for various diseases.
Protein Name: Growth Arrest Specific 2 Like 2
Functions: Involved in the cross-linking of microtubules and microfilaments (PubMed:12584248, PubMed:24706950). Regulates microtubule dynamics and stability by interacting with microtubule plus-end tracking proteins, such as MAPRE1, to regulate microtubule growth along actin stress fibers (PubMed:24706950). Enhances ADORA2-mediated adenylyl cyclase activation by acting as a scaffold to recruit trimeric G-protein complexes to ADORA2A (By similarity). Regulates ciliary orientation and performance in cells located in the airway (PubMed:30665704)
The "GAS2L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAS2L2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GAS2L3 | GAS5 | GAS6 | GAS6-AS1 | GAS7 | GAS8 | GAS8-AS1 | GASAL1 | GASK1A | GASK1B | GASK1B-AS1 | GAST | GATA1 | GATA2 | GATA2-AS1 | GATA3 | GATA3-AS1 | GATA4 | GATA5 | GATA6 | GATA6-AS1 | GATAD1 | GATAD2A | GATAD2B | GATB | GATC | GATD1 | GATD1-DT | GATD3 | GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1
